S&P 500
5.273,54 -33,47 (-0,63%) Nasdaq
16.755,46 -46,08 (-0,27%) NIKKEI 225
39.103,22 +486,12 (+1,26%) Dólar/Euro
1,0814 -0,0013 (-0,12%) Petróleo Brent
81,07 -0,83 (-1,01%) Bitcoin EUR
62.326,13 -2.078,25 (-3,23%)
Hard to Treat Diseases Inc. (HTDS)
Hard to Treat Diseases Inc.
Room EF, 12F
Jinrun Mansion Shennan Boulevard
Shenzhen 518040
China
86 755 8272 0498
https://www.mellowhope.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Shimin Yuan | Chief Executive Officer | N/A | N/A | N/A |
| Dr. Ivana Gadjanski | Communication Director | N/A | N/A | N/A |
Descripción
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.
Gobierno corporativo
El ISS Governance QualityScore de Hard to Treat Diseases Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
